Tag Archives: lupus

Sanofi Completes $600 Million Acquisition of DR-0201 to Enhance Immunology Pipeline and Advance Autoimmune Disease Treatments

(IN BRIEF) Sanofi has completed the acquisition of DR-0201 from Dren Bio, now renamed SAR448501, to enhance its immunology pipeline. This bispecific myeloid cell engager, which has shown promising results in B-cell depletion, may offer potential breakthroughs in autoimmune diseases, … Read the full press release

AstraZeneca reçoit l’approbation de l’UE pour son Saphnelo, le seul nouveau médicament depuis plus d’une décennie pour les patients atteints de lupus érythémateux disséminé

(COMMUNIQUÉ DE PRESSE) CAMBRIDGE, 16-Feb-2022 — /EuropaWire/ — AstraZeneca (LON : AZN), une multinationale pharmaceutique et biotechnologique anglo-suédoise , a annoncé l’approbation par l’Union européenne (UE) de son médicament Saphnelo (anifrolumab) en tant que traitement d’appoint pour le traitement des patients … Read the full press release

AstraZeneca receives EU approval for its Saphnelo, the only new medicine in over a decade for patients with systemic lupus erythematosus

(PRESS RELEASE) CAMBRIDGE, 16-Feb-2022 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced an European Union (EU) approval for its Saphnelo (anifrolumab) medicine as an add-on therapy for the treatment of adult patients with … Read the full press release

The only new medicine in over a decade for patients with systemic lupus erythematosus gets Food and Drug Administration (FDA) approval

(PRESS RELEASE) CAMBRIDGE, 2-Aug-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish science-led biopharmaceutical company, has announced that its Saphnelo (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus … Read the full press release

GSK: We are delighted to start the phase III study and evolve our research programme for belimumab in systemic lupus erythematosus (SLE)

LONDON, 22-Mar-2018 — /EuropaWire/ — GSK today announced the start of a phase III study investigating Benlysta (belimumab) in combination with rituximab in adult patients with systemic lupus erythematosus (SLE). Belimumab and rituximab have different but potentially complementary mechanisms of action. … Read the full press release